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Native serum Clq, the collagenous-like subcomponent of the first component of complement, is not recognized by poly- 
clonal anti-collagen type II antibodies. However, when purified Clq was subjected to limited proteolysis by collagenase 
it showed antigenic ross-reactivity with collagen type II. The same cross-reactivity was observed with hemolytically ac- 
tive Clq in synovial fluids of patients with rheumatoid arthritis (RA), whereas Clq from synovial fluids of patients with 
osteoarthritis (OA), villo-nodular synovitis and ankylosing spondylitis was not recognized by this antibody. However, 
incubation of synovial fluid Clq of OA patients with synovial fluid leucocytes from RA patients led to an alteration 
of OA-Clq which was now recognized by the anti-collagen type II antibody. 
Complement; Clq; Collagen; Collagenase; Rheumatoid arthritis 
1. INTRODUCTION 
Clq, a subcomponent of the first component of 
complement (Cl), contains a collagen-like se- 
quence of -80 amino acid residues which imparts 
to this serum protein some of the biophysical and 
biochemical characteristics of collagen [ 1,2]. 
Biosynthesis studies on Clq and collagen have 
shown that both molecules undergo similar post- 
translational steps [3-51. 
Under normal conditions serum Clq and col- 
lagen do not show any antigenic cross-reactivity, 
however under certain circumstances the structural 
similarity of collagen and Clq may result in 
biochemical and biological cross-reaction. The im- 
munological aspects of the structural relationship 
are of great interest, since auto-immunity to col- 
lagen or to the collagen-like Clq may explain both 
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the systemic nature and chronicity of the inflam- 
mation occurring especially in rheumatoid arthritis 
(RA) [6,7]. Since both molecules serve as 
substrates for collagenase, the relationship be- 
tween activated collagenase and the pathology of 
RA is of particular interest. Since activated col- 
lagenase is only found in synovial fluid of RA pa- 
tients, but not in the joint fluid of patients with 
osteoarthritis (OA) [8], one can emphasize the im- 
portance of this enzyme, which probably leads to 
an immunological cross-reactivity between Cl q 
and collagen by limited proteolysis. 
In this report we present evidence that limited 
proteolysis of serum C lq by collagenase induces an 
alteration of this molecule which leads to a cross- 
reactivity with collagen type II as measured by an 
anti-collagen type II antibody. Furthermore, we 
demonstrate that Clq in synovial fluids of patients 
with RA already contains a Clq which is recog- 
nized by the anti-collagen type II antibody. 
Leucocytes of the RA-synovial fluids were found 
to be responsible for the alteration of Clq. 
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2. MATERIALS AND METHODS 
2.1. Complement components and assays 
Sheep erythrocytes (E) sensitized with anti-E rabbit an- 
tibodies (A) were prepared as described in [9]. Cell in- 
termediates EA, EAC4 and EAClq4, as well as appropriate 
buffers, e.g. Veronal-buffered saline, VBS (ionic strength c = 
0.15; pH 7.3) and Veronal-buffered saline with sucrose, VBS-S 
(ionic strength p = 0.065; pH 7.3) were prepared as described 
in [lo]. Human Clq was purified according to Stemmer and 
Loos [11], using fast protein liquid chromatography (FPLC). 
Partially purified Clr and Cls were prepared as described in 
[12]. C2sp and C4m were isolated by a slightly modified method 
1131. Guinea pig serum with 2 mM EDTA (C-EDTA; 1: 50) was 
used as source for the late acting components C3-C9 [lo]. The 
rate of hemolysis, calculations and cell concentrations were 
used as described in 1141. 
2.2. ELBA procedures 
Purified polyclonal rabbit IgG to bovine collagen type II and 
III were kindly provided by Professor Holborow, London. 
From these antibodies F(ab’)z fragments were obtained after 
pepsin digestion in 0.1 M acetate and gel filtration on Superose 
TM12 (Pharmacia, Uppsala, Sweden) [15]. Monoclonal anti- 
Clq antibodies were raised as described in [16-181. 
Wells of the microtiter plates were coated with purified rabbit 
anti-collagen type II IgG-F(ab’)z by addition of 20~1 of a 
1: 100 dilution in 10 mM Tris-HCl, 0.13 M NaCl, pH 9.0. After 
1 h the plates were washed in the same buffer containing 
0.015070 Tween 20, 1% BSA to block remaining binding sites. 
Purified human Clq, treated with different amounts of col- 
lagenase (type III, Sigma, FRG) or buffer was added for 1 h. 
The reaction was blocked by the addition of 10 mM EDTA. 
The samples were diluted 1: 100 in 10 mM Tris-HCl, 0.13 M 
NaCI, pH 7.4, prior to use. After washing twice, the bound 
material was detected with a mixture of three different 
biotinylated monoclonal anti-Clq antibodies in a ratio of 
1: 1: 1. Biotinylation was performed as described in [19]. The 
binding of the biotinylated antibodies was determined after ad- 
dition of avidin coupled to alkaline phosphatase. 
2.3. Patients and synovial fluids 
Synovial fluid samples were collected from the knees of the 
patients at the time of a clinically indicated diagnostic puncture. 
Some of the patients were diagnosed as having classic RA ac- 
cording to the American Rheumatism Association classification 
criteria 1201. The others were diagnosed as having unilateral or 
bilateral OA, psoriatic arthritis, villa-nodular synovitis or 
ankylosing spondylitis. The samples were tested immediately 
after collection. 
3. RESULTS 
Purified Clq was subjected to an enzymatic 
alteration by collagenase. In order to measure the 
influence of the enzyme on cell-bound Clq, which 
enables us to wash out the enzyme at any given 
time, the following assay was performed: EAClq4 
was prepared by incubation of EAC4 with purified 
; 
Fig.1. Dose-dependent inhibition of Ci (Clq) hemolytic activity 
after treatment with collagenase: EAClq4 preparations (100 
effective Clq molecules per cell) were treated with different 
amounts of collagenase. Control 1 was treated with VBS-S 
instead of collagenase and anti-collagenase II diluted 1: 100 in 
the same buffer. Control 2 was treated with buffer alone. 
Control 3 was treated with lOOrg/ml collagenase and VBS-S 
instead of anti-collagenase II. After washing twice, purified 
anti-collagen type II IgG (1: 100 in VBS-S) was added. Again 
the cells were washed and after addition of Clr, Cls, C2 and 
the late acting complement components, Cl activity was 
determined. 
Clq (100 effective molecules per cell) for 10 min at 
30°C in VBS-S. The cells were washed, resuspend- 
ed with VBS-S and incubated with different 
amounts of collagenase for 2 h at 30°C. Controls 
were treated with buffer. After washing twice the 
cells were incubated with the purified anti-collagen 
type II IgG (1: 100 diluted in VBS-S, additional 
controls were treated with buffer) for 30 min at 
30°C. Again, the cells were washed twice and the 
hemolytic Clq activity was determined. Fig. 1 
shows that the anti-collagen type II antibody does 
not inhibit the activity of bound Clq. However, 
when bound Clq was pretreated with collagenase 
then inhibition of Clq activity by the anti-collagen 
type II antibody was observed. The extent of in- 
hibition was dependent upon the concentration of 
collagenase used. Collagenase by itself had no ef- 
fect on Clq activity. In additional experiments it 
was found that purified anti-collagen type III an- 
tibodies had no effect on collagenase treated 
bound Clq (not shown; see also fig.3). 
The recognition of collagenase-altered Clq with 
the anti-collagen type II antibody could also be 
demonstrated in a biotin-avidin ELISA system. 
Plates covered with anti-collagen type II F(ab ‘)2 
antibody fragments (50 fig/ml) were incubated 
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with collagenase (0.01 to lOO~g/ml) pretreated 
Clq (30 min at 30°C). Binding of Clq was 
monitored with biotinylated monoclonal anti-Clq 
antibodies (fig.2). Again only collagenase-treated 
Clq was recognized by anti-collagen type II an- 
tibodies. The use of the F(ab’)z fragments ex- 
cluded Fc-mediated binding of Clq of the 
anti-collagen antibody. 
Auto-antibodies against collagen type II are well 
documented in the literature and are thought to 
contribute to the pathogenic mechanisms causing 
RA [6,7]. The generation of auto-antibodies could 
be due to enzymatic alterations of collagen or 
collagen-like material. One of the candidates caus- 
ing such an alteration is collagenase, which occurs 
in a high concentration and in the activated form 
within the synovial fluids during the acute phase of 
inflammation [8]. Since we were able to show in 
vitro the recognition of collagenase-treated human 
Clq by an anti-bovine collagen type II antibody, 
- 
I 
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Fig.2. Recognition of cohagenase-treated Clq by the anti- 
collagen type II F(ab’)z-fragments. Collagenase-treated Clq 
was bound by the anti-collagen type II F(ab ‘)z coated on wells. 
Binding was detected with biotinylated anti-Clq monoclonal 
antibodies. Buffer-treated Clq as well as anti-collagen type III 
antibody (IgG-fraction) served as control. 
I 
10-b 
antibody - dilution 
Fig.3. Inhibition of CT (Clq) hemolytic activity by the anti-collagen type II antibody in an RA-synovial fluid. Clq within the 
EAC 1 -complex from the synovial fluid of patients with RA ( H), OA, ankylosing spondylitis, and villa-nodular synovitis (C--O) 
were tested for their reactivity with the anti-collagen type II antibody in the hemolytic assay. As an additional control all samples were 
tested for their reactivity with an anti-collagen type III antibody (M). 
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we investigated the influence of this antibody on 
Clq in macromolecular Cl from the synovial fluid 
of patients with RA, OA, psoriatic arthritis, villo- 
nodular synovitis and ankylosing spondylitis. 
EAClii, (z = 1) preparations were prepared by 
incubating the individual synovial fluids with EA 
for 10 min at 30°C. 100~1 of each EAClrim 
preparation were incubated with different amounts 
of anti-purified collagen type II IgG for 30 min at 
30°C. After washing twice, the hemolytic Cl ac- 
tivity was determined. Fig.3 shows that only the 
hemolytic CT activity from the synovial fluid of the 
patient with RA could be inhibited by the an- 
tibody. Cl from NHS as well as from the synovial 
fluids from the other patients were not affected by 
the anti-collagen type II antibody. As an addi- 
tional control, all samples were tested for their 
reactivity with purified anti-collagen type III IgG. 
No reaction could be observed (fig.3). 
The cellular composition in the synovial fluids 
of RA patients plays a crucial role in diagnosis: in 
the acute phase the ratio of granulocytes versus 
lymphocytes is found to be at least 8 : 1. Since 
granulocytes are described as secreting collagenase 
[8], we considered these cells to cause the alteration 
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Fig.4. Influence of the leucocytes from an RA-synovial fluid on 
the reactivity of Clq from an OA joint fluid with the anti- 
collagen type II antibody. Leucocytes were transferred from 
RA- to OA-synovial fluid and incubated for 3 h at 37°C. The 
cells were spun down and the supernatant was tested in the 
hemolytic assay. Control was performed by OA leucocytes in 
OA-joint fluid for 3 h at 37°C. (M) Control; (o--O) 
transfer. A dose-dependent decrease of the Cl (Clq) hemolytic 
activity can only be observed in the transfer experiment. 
of synovial fluid Clq. To test this hypothesis, the 
following experiment was performed: cells from 
synovial fluid of RA patients were spun down. 
After discharging the supernatant, the cells were 
washed three times and adjusted to a concentration 
of 1.0 x lO’/ml. These cells were incubated with 
the OA-synovial fluid (as source of Cl or C lq) 
from which the cells had been removed by cen- 
trifugation for 3 h at 37°C. After centrifugation, 
the supernatant was incubated with EA to form 
EACl . Equal volumes of EACl were incubated 
with different dilutions of purified anti-collagen 
type II IgG. After washing the remaining Cl activi- 
ty was determined. Fig.4 shows that incubation of 
OA-synovial fluid with granulocytes from the RA 
patient led to a recognition of the OA-Cl (Clq) by 
purified anti-collagen type II IgG resulting in an 
inhibition of its hemolytic activity. 
4. DISCUSSION 
Native Clq, the collagen-like subcomponent of 
the first component of complement, is not 
recognized by an anti-collagen type II antibody. In 
this report we raised the question of whether en- 
zymatic treatment of Clq with collagenase alters 
its antigenic behaviour in such a way that Clq now 
shares epitope(s) with collagen type II. Treatment 
of cell-bound Clq (EAClq4) or fluid-phase Clq 
with different concentrations of collagenase 
resulted in a dose-dependent recognition of C 1 q by 
an anti-collagen type II antibody (figs 1 and 2). 
Collagenase (100 pg/ml, 3 h at 37°C) by itself had 
no effect on the hemolytic activity of cell-bound 
Clq. The hemolytic activity of collagenase-treated 
Clq was blocked by the anti-collagen type II an- 
tibody depending on the concentration of col- 
lagenase used for Clq treatment. 
Comparing Clq from synovial fluids of dif- 
ferent rheumatic diseases revealed that only Clq 
from synovial fluids of RA patients was recognized 
by the anti-collagen type II antibody (fig.3). This 
indicated that within the synovial fluid of RA pa- 
tients an alteration of Clq takes place resulting in 
cross-reactivity with collagen type II. The pro- 
teolytic alteration of Clq could be achieved by the 
leukocytes separated from the synovial fluids of an 
RA patient (fig.4). Since granulocytes represent 
the predominant cell population within synovial 
fluids of RA patients, the granulocyte-derived col- 
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lagenase must be considered to cause an alteration 
in the collagenous portion of the Clq molecule. 
This interpretation is in agreement with the ob- 
servations that ‘activated’ collagenase derived 
from granulocytes is present in the joint fluids of 
RA patients [HI. To confirm this assumption ex- 
periments are planned using purified granulocyte- 
derived collagenase. 
So far, there is only one report showing cellular 
immune response after intradermal immunisation 
of guinea pigs with the collagen-like Clq 
fragments [21]. In this report a cross-reactivity to 
collagen type I was observed. 
Our in vitro and in vivo observations how that 
limited proteolysis of Clq with collagenase reveals 
common epitope(s) with collagen type II. Even 
when an antibody against bovine collagen type II 
was used in this study, the observed cross- 
reactivity with human C 1 q after limited proteolysis 
indicates that within the collagen-like portion of 
Clq common epitopes with collagen type II are 
present. There are several reports in the literature 
describing the induction of a collagen-induced ar- 
thritis using heterologous collagen type II prepara- 
tions [22]. The observations described in this 
report raise the question as to whether collagenase- 
altered Clq is involved in the pathomechanism of 
rheumatoid arthritis. 
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